PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.47%
R&D growth above 1.5x CRVO's 5.59%. Michael Burry would check for spending discipline.
-1.59%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.64%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
14.64%
Similar total costs growth to CRVO's 15.98%. Walter Schloss would investigate norms.
No Data
No Data available this quarter, please select a different quarter.
8.11%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
-14.78%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-24.66%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-15.16%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
14.88%
Tax expense change of 14.88% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
-15.16%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
2.78%
EPS growth while CRVO declines. John Neff would investigate advantages.
2.78%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
19.07%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
19.07%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.